EFFECTS OF THE DUAL ENDOTHELIN ANTAGONIST APROCITENTAN ON AMBULATORY BLOOD PRESSURE INDICES IN PATIENTS WITH RESISTANT HYPERTENSION. RESULTS FROM THE PRECISION STUDY

被引：0
|
作者：
Schlaich, Markus [1 ]
Weber, Michael A. [2 ]
Bakris, George L. [3 ]
Flack, John M. [4 ]
Lu, Wentao [5 ]
Haskell, Lloyd P. [6 ]
Wang, Ji-Guang [7 ]
Narkiewicz, Krzysztof [8 ]
机构：
[1] Univ Western Australia, Royal Perth Hosp Res Fdn, Sch Med, Dobney Hypertens Ctr, Perth, WA, Australia
[2] SUNY, Downstate Coll Med, Brooklyn, NY USA
[3] Univ Chicago Med, Dept Med, Amer Heart Assoc Comprehens Hypertens Ctr, Chicago, MI USA
[4] Southern Ill, Hypertens Sect, Div Gen Internal Med, Dept Med, Springfield, IL USA
[5] Janssen Res & Dev LLC, Raritan, NJ USA
[6] Janssen Pharmaceut Co Johnson & Johnson, Raritan, NJ USA
[7] Shanghai Jiaotong Univ Scho, Shanghai Inst Hypertens, Rui Jin Hosp, Dept Hypertens, Shanghai, Peoples R China
[8] Med Univ Gdansk, Dept Hypertens & Diabetol, Gdansk, Poland
来源：
JOURNAL OF HYPERTENSION | 2023年 / 41卷
关键词：
D O I：
暂无
中图分类号：
R6 [外科学];
学科分类号：
1002 ; 100210 ;
摘要：
引用
收藏
页码：E71 / E71
页数：1
相关论文
共 50 条
  • [1] Effects Of Aprocitentan, A Dual Endothelin Receptor Antagonist, On Blood Pressure In Black/African American Patients With Resistant Hypertension: Results From A Randomized, Controlled Study (PRECISION) Including A Withdrawal Phase
    Flack, John M.
    Schlaich, Markus
    Weber, Michael
    Bakris, George
    Lu, Wentao
    Sassi-Sayadi, Mouna
    Haskell, Lloyd
    Narkiewicz, Krzysztof
    Dreier, Roland F.
    Wang, Ji-Guang
    [J]. HYPERTENSION, 2023, 80
  • [2] Percentage of Patients Achieving Blood Pressure Goals With Aprocitentan, a Dual Endothelin Receptor Antagonist: Results From a Randomized, Controlled Phase 3 Study (PRECISION)
    Weber, Michael A.
    Wang, Jiguang
    Flack, John M.
    Schlaich, Markus
    Bakris, George
    Lu, Wentao
    Haskell, Lloyd
    Narkiewicz, Krzysztof
    [J]. CIRCULATION, 2023, 148
  • [3] Sustained Blood Pressure Lowering Effect With the Dual Endothelin Receptor Antagonist Aprocitentan in Resistant Hypertension: Results From a Randomized, Controlled Study Including a Withdrawal Phase
    Schlaich, Markus P.
    Bellet, Marc
    Weber, Michael A.
    Danaietash, Parisa
    Bakris, George L.
    Flack, John M.
    Dreier, Roland F.
    Sassi-Sayadi, Mouna
    Haskell, Lloyd P.
    Narkiewicz, Krzysztof
    Wang, Jiguang
    [J]. CIRCULATION, 2022, 146 (25) : E583 - E584
  • [4] Investigating the endothelin receptor antagonist aprocitentan in resistant hypertension: design and baseline characteristics of the PRECISION study
    Danaietash, P.
    Verweij, P.
    Wang, J.
    Dresser, G.
    Kantola, I.
    Lawrence, M. K.
    Narkiewicz, K.
    Schlaich, M.
    Bellet, M.
    [J]. EUROPEAN HEART JOURNAL, 2021, 42 : 2362 - 2362
  • [5] Aprocitentan (a Dual Endothelin-Receptor Antagonist) for Treatment-Resistant Hypertension
    McCoy, Emily K.
    Lisenby, Katelin M.
    [J]. JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 2021, 77 (06) : 699 - 766
  • [6] Aprocitentan Dual endothelin ETA/ETB receptor antagonist Treatment of resistant hypertension
    Warden, B. A.
    Duell, P. B.
    [J]. DRUGS OF THE FUTURE, 2021, 46 (08) : 595 - 611
  • [7] Aprocitentan, A Dual Endothelin Receptor Antagonist Under Development for the Treatment of Resistant Hypertension
    Angeli, Fabio
    Verdecchia, Paolo
    Reboldi, Gianpaolo
    [J]. CARDIOLOGY AND THERAPY, 2021, 10 (02) : 397 - 406
  • [8] Aprocitentan, A Dual Endothelin Receptor Antagonist Under Development for the Treatment of Resistant Hypertension
    Fabio Angeli
    Paolo Verdecchia
    Gianpaolo Reboldi
    [J]. Cardiology and Therapy, 2021, 10 : 397 - 406
  • [9] Population pharmacokinetics of the dual endothelin receptor antagonist aprocitentan in subjects with or without essential or resistant hypertension
    Brussee, Janneke M.
    Sidharta, Patricia N.
    Dingemanse, Jasper
    Krause, Andreas
    [J]. JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS, 2024, 51 (03) : 243 - 252
  • [10] Dual endothelin antagonist aprocitentan for resistant hypertension (PRECISION): a multicentre, blinded, randomised, parallel-group, phase 3 trial
    Schlaich, Markus P.
    Bellet, Marc
    Weber, Michael A.
    Danaietash, Parisa
    Bakris, George L.
    Flack, John M.
    Dreier, Roland F.
    Sassi-Sayadi, Mouna
    Haskell, Lloyd P.
    Narkiewicz, Krzysztof
    Wang, Ji-Guang
    [J]. LANCET, 2022, 400 (10367): : 1927 - 1937
12345